SynthesisCancer research2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Open access · bronzeAbstract readMeta-Analysis
In one paragraph
Synthesis in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Genetic variation inGut · 2023Pooled it
- Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.NPJ genomic medicine · 2025Article
- Exome sequencing reveals new insights into the germline landscape of inflammatory breast cancer among Tunisian patients.Journal of translational medicine · 2025Article
- Inherited Susceptibility to Cancer: Past, Present and Future.Annals of human genetics · 2025Review
- Exploring the Role of CDO1 in Breast Cancer: Insights into Tumor Biology and Therapeutic Potential.Annals of surgical oncology · 2025Article
- Photodynamic Therapy and Dietary Antioxidants: A Dual Strategy for Genome Stability and DNA Damage Repair.Cancer medicine · 2025Review
- Investigation of a germline variant of uncertain significance (MRE11:c.1138C > T) identified by exome sequencing in a cancer-affected individual and co-segregation analysis in affected and unaffected family members.Molecular biology reports · 2025Article
- Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma.JAMA otolaryngology-- head & neck surgery · 2025Article
- Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.Annals of hematology · 2024Article
- Review
- Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent.Cell death and differentiation · 2024Review
- Exploring the frequency of a TP53 polyadenylation signal variant in tumor DNA from patients diagnosed with lung adenocarcinomas, sarcomas and uterine leiomyomas.Genetics and molecular biology · 2024Article
- Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer.Genome biology · 2023Article
- Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.Cancer research · 2023Article
- Pathogenic variant profile in DNA damage response genes correlates with metastatic breast cancer progression-free survival in a Mexican-mestizo population.Frontiers in oncology · 2023Article
- Epigenetic germline variants predict cancer prognosis and risk and distribute uniquely in topologically associating domains.F1000Research · 2023Article
- Women in the European Virus Bioinformatics Center.Viruses · 2022Article
- Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer.Cancers · 2022Article
- Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis.Scientific reports · 2022Observational
- An integrated somatic and germline approach to aid interpretation of germline variants of uncertain significance in cancer susceptibility genes.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 14 institutions in 4 countries.
Ping ZhangLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.ORCID 0000-0001-7063-7769
Isaac Kitchen-SmithLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Lingyun XiongLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.ORCID 0000-0003-4594-4120
Giovanni StracquadanioLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Katherine BrownWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Philipp H RichterLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Marsha D WallaceLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Elisabeth BondLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Natasha SahgalLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Samantha MooreLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Svanhild NornesLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Sarah De ValLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Mirvat SurakhyLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.ORCID 0000-0001-7101-984X
David SimsWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Xuting WangEnvironmental Epigenomics and Disease Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences-National Institutes of Health, Research Triangle Park, North Carolina.
Douglas A BellEnvironmental Epigenomics and Disease Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences-National Institutes of Health, Research Triangle Park, North Carolina.
Jorge Zeron-MedinaLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Yanyan JiangCRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, Oxford, United Kingdom.
Anderson J RyanCRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, Oxford, United Kingdom.ORCID 0000-0001-6241-7969
Joanna L SelfeSarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
Janet ShipleySarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
Siddhartha KarDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Paul D PharoahDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8494-732X
Chey LovedayDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-2291-372X
Rick JansenAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, the Netherlands.
Lukasz F GrocholaDepartment of Surgery, Cantonal Hospital Winterthur, Switzerland.ORCID 0000-0002-7606-7266
Claire PallesInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-9670-2263
Andrew ProtheroeOxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Val MillarTarget Discovery Institute, University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom.
Daniel V EbnerTarget Discovery Institute, University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom.ORCID 0000-0002-6495-7026
Meghana PagadalaDepartment of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-7591-6035
Sarah P BlagdenDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-8783-3491
Timothy S MaughanDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-0580-5065
Enric DomingoDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-4390-8767
Ian TomlinsonInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0003-3037-1470
Clare TurnbullDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
Hannah CarterDepartment of Medicine, University of California, San Diego, La Jolla, California. G.Bond.1@bham.ac.uk hkcarter@health.ucsd.edu.ORCID 0000-0002-1729-2463
Gareth L BondLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom. G.Bond.1@bham.ac.uk hkcarter@health.ucsd.edu.
Ludwig Cancer Research · GBInstitute of Cancer Research · GBUniversity of Oxford · GBCancer Research UK · GBCancer Research UK Clinical Trials Unit · GBCRUK/MRC Oxford Institute for Radiation Oncology · GBJohn Radcliffe Hospital · GBNational Institute of Environmental Health Sciences · USNuffield Orthopaedic Centre · GBUniversity of California San Diego · USUniversity of Cambridge · GBAmsterdam Neuroscience · NLKantonsspital Winterthur · CHOxford University Hospitals NHS Trust · GB
Funding
Discovery And Functional Genomics Of Environmental Response GenesZIAES100475 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BELL, DOUGLAS · 2009 to 2025
$24.4MPredoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5MDiscovery And Genetics Of Environmental Response GenesZ01ES100475 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BELL, DOUGLAS · 2002 to 2008
$2.9MNetwork approaches to identify cancer drivers from high-dimensional tumor dataDP5OD017937 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARTER, HANNAH KATHRYN · 2013 to 2017
$1.9MBritish Heart Foundation FS/17/35/32929Cancer Research UK 16561Intramural NIH HHS Z01 ES100475Medical Research Council MC_PC_12006Medical Research Council MC_PC_15065Medical Research Council MC_UU_00001/6Medical Research Council MR/M016587/1NCI NIH HHS T32 CA067754NIH HHS DP5 OD017937
Abstract
Insights into oncogenesis derived from cancer susceptibility loci (SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic insights have thus far been limited by our current lack of understanding regarding both interactions of these loci with somatic cancer driver mutations and their influence on tumorigenesis. For example, although both germline and somatic genetic variation to the p53 tumor suppressor pathway are known to promote tumorigenesis, little is known about the extent to which such variants cooperate to alter pathway activity. Here we hypothesize that cancer risk-associated germline variants interact with somatic
Indexed as
AnimalsAntineoplastic AgentsBiomarkers, PharmacologicalCarcinogenesisCase-Control StudiesCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGerm-Line MutationHumansMaleMiceMice, Inbred BALB CAntineoplastic AgentsBiomarkers, PharmacologicalTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.